<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347779">
  <stage>Registered</stage>
  <submitdate>29/11/2011</submitdate>
  <approvaldate>30/11/2011</approvaldate>
  <actrnumber>ACTRN12611001229965</actrnumber>
  <trial_identification>
    <studytitle>Penehyclidine Hydrochloride reduces the incidence of intraoperative awareness</studytitle>
    <scientifictitle>Penehyclidine Hydrochloride reduces the incidence of intraoperative awareness in patients undergoing breast cancer surgery during general anesthesia</scientifictitle>
    <utrn>U1111-1126-1353</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>breast cancer</healthcondition>
    <healthcondition>awareness during surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients receive 0.01 mg.kg-1 Penehyclidine Hydrochloride intravenously 30min before surgery</interventions>
    <comparator>Patients receive 0.01 mg.kg-1 saline intravenously 30min before surgery</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Penehyclidine Hydrochloride reduces the incidence of intraoperative awareness in patients undergoing breast cancer surgery during general anesthesia.</outcome>
      <timepoint>Every Patient was interviewed twice, at anytime between 2 and 6 hours postoperatively and at any time between 24 and 48 hours postoperatively.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patients with higher degree anxiety levels were liable to report intraoperative awareness.</outcome>
      <timepoint>Before they received Penehyclidine Hydrochloride or saline, the patients were assessed preoperative anxiety levels by using a 100-mm visual analogue scale.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>American Society of Anesthesiologists physical status IIII patients, aged 1575 years, undergoing breast cancer surgery</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>psychosis or memory impairment, history of intraoperative awareness or brain injury, history of electroencephalographic abnormality, patients habitually using benzodiazepines, opiates, alcohol, barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampicin etc.  and patients who are unable to provide informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment was established by placing the randomization sequence in consecutively numbered, opaque envelopes.</concealment>
    <sequence>computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>21/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>900</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Zhiming Tan</primarysponsorname>
    <primarysponsoraddress>Department of Anesthesiology, Fudan University Cancer Hospital, No.270 Dong-an Road, Shanghai, P. R. China</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Fudan University Cancer Hospital</fundingname>
      <fundingaddress>No.270 Dong-an Road, Shanghai, P. R. China</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Jing wang</sponsorname>
      <sponsoraddress>Department of Anesthesiology, Fudan University Cancer Hospital, No.270 Dong-an Road, Shanghai, P. R. China</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Yu Ren,Minmin Zhu,Yun Zhu,Jiawei Chen,Yajun Xu</othercollaboratorname>
      <othercollaboratoraddress>Department of Anesthesiology, Fudan University Cancer Hospital, No.270 Dong-an Road, Shanghai, P. R. China</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Extensive evidence has proved that basal forebrain cholinergic system play extremely important role in explicit memory.Penehyclidine hydrochloride (PHC; (2-hydroxyl-2-cyclopentyl-2-phenyl-ethoxy) quinuclidine) is a new anticholinergic drug with both antimuscarinic and antinicotinic activity while retaining potent central and peripheral anticholinergic activity.The primary purpose of this study is to verify the effectiveness of PHC reducing the incidence of intraoperative awareness. Modified Brice interview was used to assess awareness in the study.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>the Cancer Hospital, Fudan University Institutional Human Ethics Committee</ethicname>
      <ethicaddress>No.270 Dong-an Road, Shanghai, P. R. China,PC 200032.</ethicaddress>
      <ethicapprovaldate>20/01/2010</ethicapprovaldate>
      <hrec>YJ200906</hrec>
      <ethicsubmitdate>23/11/2009</ethicsubmitdate>
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Zhiming Tan</name>
      <address>Department of Anesthesiology, Fudan University Cancer Hospital, No.270 Dong-an Road, Shanghai, P. R. China, PC 200032.</address>
      <phone>86-21-64175590(for Shanghai ,China)</phone>
      <fax />
      <email>zmtan166@163.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>YuRen</name>
      <address>Department of Anesthesiology, Fudan University Cancer Hospital, No.270 Dong-an Road, Shanghai, P. R. China, PC 200032.</address>
      <phone>86-21-64175590(for Shanghai ,China)</phone>
      <fax />
      <email>nancy1248@sina.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Zhiming Tan</name>
      <address>Department of Anesthesiology, Fudan University Cancer Hospital, No.270 Dong-an Road, Shanghai, P. R. China, PC 200032.</address>
      <phone>86-21-64175590(for Shanghai ,China)</phone>
      <fax />
      <email>zmtan166@163.com</email>
      <country>China</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>